While most proteomics companies have their sights on the multi-million dollar drug in the sky, a few firms are making the case that the low-hanging fruit — diagnostic protein markers — might be just as worthwhile a goal. Using proteomics technology, both Matritech of Newton, Mass., and Syn X Pharma of Toronto have discovered disease markers and successfully marketed them to partners, in return for hard cash.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.